RxDoctor Payments Data

Jesus Zavaleta, MD

Family Medicine · McAllen, TXNPI 1023010683

Payments from drug & device makers

$705in general payments, 2019–2025

Across 46 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$329
  • Johnson & Johnson$95
  • Lilly USA, LLC$82
  • AstraZeneca$60
  • Pfizer$59
  • Boehringer Ingelheim$33
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$69498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$705 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$101,917
Medicare patients
240
Services billed
1,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$217,499
JardianceEmpagliflozin96$103,957
MounjaroTirzepatide73$89,227
FarxigaDapagliflozin Propanediol43$55,000
Bydureon BciseExenatide Microspheres13$25,996
XareltoRivaroxaban17$23,504
EliquisApixaban16$18,976
MyrbetriqMirabegron12$11,685
LinzessLinaclotide13$11,046
JanuviaSitagliptin Phosphate15$10,825
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$10,734
JanumetSitagliptin Phos/Metformin Hcl12$10,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,740
Levemir FlexpenInsulin Detemir13$4,506
Novolog FlexpenInsulin Aspart14$3,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$329$217,499156 claims
Boehringer IngelheimJardiance$33$103,95796 claims
Lilly USA, LLCMounjaro$82$89,22773 claims
AstraZenecaFarxiga$60$55,00043 claims
Johnson & JohnsonXarelto$95$23,50417 claims
PfizerEliquis, Paxlovid$59$21,83473 claims
MerckJanuvia, Janumet$24$21,04527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →